317 related articles for article (PubMed ID: 21860463)
1. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton.
Hegde NS; Sanders DA; Rodriguez R; Balasubramanian S
Nat Chem; 2011 Aug; 3(9):725-31. PubMed ID: 21860463
[TBL] [Abstract][Full Text] [Related]
2. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
3. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
4. FoxM1 inhibitors as potential anticancer drugs.
Gartel AL
Expert Opin Ther Targets; 2008 Jun; 12(6):663-5. PubMed ID: 18479213
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
Jiang L; Wang P; Chen L; Chen H
Int J Clin Exp Pathol; 2014; 7(9):5450-60. PubMed ID: 25337187
[TBL] [Abstract][Full Text] [Related]
7. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells.
Bhat UG; Halasi M; Gartel AL
PLoS One; 2009; 4(5):e5592. PubMed ID: 19440351
[TBL] [Abstract][Full Text] [Related]
8. Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.
Maekawa A; Kohashi K; Setsu N; Kuda M; Iura K; Ishii T; Matsunobu T; Nakatsura T; Iwamoto Y; Oda Y
Cancer Sci; 2016 Jan; 107(1):95-102. PubMed ID: 26560505
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
[TBL] [Abstract][Full Text] [Related]
10. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.
Chen Y; Ruben EA; Rajadas J; Teng NNH
Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623
[TBL] [Abstract][Full Text] [Related]
11. Thiostrepton, proteasome inhibitors and FOXM1.
Gartel AL
Cell Cycle; 2011 Dec; 10(24):4341-2. PubMed ID: 22134246
[No Abstract] [Full Text] [Related]
12. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.
Wang WD; Shang Y; Wang C; Ni J; Wang AM; Li GJ; Su L; Chen SZ
Acta Pharmacol Sin; 2022 Nov; 43(11):2956-2966. PubMed ID: 35422085
[TBL] [Abstract][Full Text] [Related]
13. A novel mode of FoxM1 regulation: positive auto-regulatory loop.
Halasi M; Gartel AL
Cell Cycle; 2009 Jun; 8(12):1966-7. PubMed ID: 19411834
[TBL] [Abstract][Full Text] [Related]
14. Liposomal Thiostrepton Formulation and Its Effect on Breast Cancer Growth Inhibition.
Wongkhieo S; Numdee K; Lam EWF; Choowongkomon K; Kongsema M; Khongkow M
J Pharm Sci; 2021 Jun; 110(6):2508-2516. PubMed ID: 33515584
[TBL] [Abstract][Full Text] [Related]
15. Untying the knot of transcription factor druggability: Molecular modeling study of FOXM1 inhibitors.
Tabatabaei-Dakhili SA; Aguayo-Ortiz R; Domínguez L; Velázquez-Martínez CA
J Mol Graph Model; 2018 Mar; 80():197-210. PubMed ID: 29414039
[TBL] [Abstract][Full Text] [Related]
16. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
[TBL] [Abstract][Full Text] [Related]
17. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Uddin S; Hussain AR; Ahmed M; Siddiqui K; Al-Dayel F; Bavi P; Al-Kuraya KS
Haematologica; 2012 Jul; 97(7):1092-100. PubMed ID: 22271891
[TBL] [Abstract][Full Text] [Related]
20. FoxM1 is a general target for proteasome inhibitors.
Bhat UG; Halasi M; Gartel AL
PLoS One; 2009 Aug; 4(8):e6593. PubMed ID: 19672316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
